RxDoctor Payments Data

Pedro Vargas-Otero, MD

Cardiovascular Disease · San Juan, PRNPI 1548493729

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (54.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Boston Scientific at 27.4% of the total. Reporting peaked in 2019 at $6,317 and has fallen 86.3% since, to $868 in 2025. Among cardiovascular disease clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,000in general payments, 2019–2025

Across 201 payments — averaging $74.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Medtronic$4K
  • Abbott$3K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Edwards Lifesciences$678
  • Bayer$360
  • plus $2K from 15 others

What the payments were for

  • Speaking & faculty fees$3,75025%
  • Travel & lodging$3,13121%
  • Food & beverage$8,11954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific10$4,110
Medtronic(2 entities)29$3,882
Abbott26$2,638
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)49$1,328
Edwards Lifesciences12$678
Bayer3$360
Boehringer Ingelheim11$325
Johnson & Johnson6$311
PBG Puerto Rico LLC12$266
AstraZeneca12$197
Amgen2$151
E.r. Squibb & Sons, L.L.C.8$141
Novartis7$133
Pfizer Pharmaceuticals LLC1$125
United Therapeutics Corporation1$100
Scpharmaceuticals Inc.4$90
Merck4$74
Dexcom, Inc.1$28
Bayer Puerto Rico Inc.1$25
Johnson And Johnson International1$20
Sanofi-aventis U.S. LLC1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,000 in reported general payments places this provider in the 90th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$14,903
Medicare patients
58
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$33,901
EntrestoSacubitril/Valsartan18$14,950
JardianceEmpagliflozin18$13,634
BrilintaTicagrelor14$6,401
Metoprolol Succinate94$1,159
Atorvastatin Calcium112$1,021
Losartan Potassium68$523
Rosuvastatin Calcium48$512
Spironolactone30$346
Carvedilol43$342
Ezetimibe15$341
Enalapril Maleate11$300
Warfarin Sodium31$235
Amlodipine Besylate41$214
Hydralazine Hcl17$181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$133$14,95018 claims
Boehringer IngelheimJardiance$325$13,63418 claims
AstraZenecaBrilinta$197$6,40114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →